Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies
View Patent ↗This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.
1. An adsorbent for selective removal of anti-von Willebrand Factor cleaving protease antibodies from human plasma, wherein the adsorbent comprise a human von-Willebrand Factor-cleaving protease fragment that consists of amino acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 chemically coupled to an inert matrix material.
2. The adsorbent according to claim 1 , wherein said fragment is a recombinant fragment.
3. The adsorbent according to claim 1 , wherein said matrix material is selected form the group consisting of carbohydrates, silicates, glasses and organic polyreaction products.
4. The adsorbent according to claim 3 , wherein said carbohydrates comprise cross-linked modified agarose.
5. The adsorbent according to claim 1 , wherein said matrix material is present in the form of porous beads.
6. The adsorbent according to claim 1 , wherein said fragment is coupled directly or indirectly via a spacer to said matrix material.
7. A method for selective removal of anti-von Willebrand Factor-cleaving protease antibodies from human plasma, comprising the steps of: (a) providing a plasma from whole blood from a patient having a disorder associated with occurrence of anti-von Willebrand Factor-cleaving protease antibodies; (b) subjecting said plasma to an affinity chromatography using an adsorbent comprising a human von-Willebrand Factor-cleaving protease fragment that consists of amino acid sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 chemically coupled to an inert matrix material; wherein the affinity chromatography is performed under physiological conditions in which the antibodies bind to human von Willebrand Factor-cleaving protease; and (c) collecting a flow-through fraction which is essentially devoid of anti-von Willebrand Factor-cleaving protease antibodies.
8. The method of claim 7 , wherein said fragment is a recombinant fragment.
9. The method according to claim 7 , wherein PBS is a binding buffer in step (b).
10. The method according to claim 7 , wherein the adsorbent is regenerated by eluting the bound antibodies and re-equilibrating in PBS.
11. The method according to claim 7 , wherein the disorder is a thromboembolic disease.
12. The method according to claim 11 , wherein the thromboembolic disease is selected from the group consisting of thrombotic thrombocytic purpua, Henoch-Schonlein pupura, preeclampsia, and neonatal thrombocytopenia.
13. The method according to claim 7 , wherein said matrix material is selected form the group consisting of carbohydrates, silicates, glasses and organic polyreaction products.
14. The method according to claim 13 , wherein said carbohydrates comprise cross-linked modified agarose.
15. The method according to claim 7 , wherein said matrix material is present in the form of porous beads.